![Toni Choueiri: Dr. Arlene Siefker-Radtkr presents the results of THOR](https://oncodaily.com/pub/uploads/2023/10/F88bVt9WgAAJ9x8-e1698169720805-1280x838.jpg)
Photo taken from Toni Choueiri/Twitter
Oct 24, 2023, 13:48
Toni Choueiri: Dr. Arlene Siefker-Radtkr presents the results of THOR
Quoting Toni Choueiri, the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute, on X/Twitter:
“To kick-off an exciting GU proffered session: Dr. Arlene Siefker-Radtkr presents the results of THOR:
– No OS benefit for erdafitinib vs pembro,
– Increased response rate with erdafitinib,
– While fewer responses to pembro, response is more durable.”
Source: Toni Choueiri/Twitter
Jul 4, 2024, 00:09